Drugmakers Aren’t Buying What the White House Is Selling on MFN

And a price war of sorts is emerging as Arrowhead and Ionis prepare to enter a large CV disease market

Mar 31, 2026

Subscribe to Cost Curve Apex to read the rest.

Upgrade to Apex to get access to this post and other subscriber-only content.